Tarsus Pharmaceuticals Inc (NASDAQ: TARS) on Friday, soared 5.24% from the previous trading day, before settling in for the closing price of $44.12. Within the past 52 weeks, TARS’s price has moved between $20.08 and $57.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 172.29%. The company achieved an average annual earnings per share of 46.82%. With a float of $35.81 million, this company’s outstanding shares have now reached $38.35 million.
Considering the fact that the conglomerate employs 323 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 92.99%, operating margin of -65.9%, and the pretax margin is -63.16%.
Tarsus Pharmaceuticals Inc (TARS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tarsus Pharmaceuticals Inc is 13.92%, while institutional ownership is 94.71%. The most recent insider transaction that took place on Mar 24 ’25, was worth 300,000. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $50.00, taking the stock ownership to the 824,106 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 6,000 for $50.00, making the entire transaction worth $300,000.
Tarsus Pharmaceuticals Inc (TARS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.82% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Tarsus Pharmaceuticals Inc (TARS) is currently performing well based on its current performance indicators. A quick ratio of 4.39 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach 1.24 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Compared to the last year’s volume of 0.68 million, its volume of 0.89 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 43.20%. Additionally, its Average True Range was 3.56.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 35.80%, which indicates a significant decrease from 50.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.68% in the past 14 days, which was higher than the 53.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.60, while its 200-day Moving Average is $40.87. Nevertheless, the first resistance level for the watch stands at $47.72 in the near term. At $49.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $51.41. If the price goes on to break the first support level at $44.02, it is likely to go to the next support level at $41.61. Now, if the price goes above the second support level, the third support stands at $40.33.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
Market capitalization of the company is 1.93 billion based on 38,377K outstanding shares. Right now, sales total 182,950 K and income totals -115,550 K. The company made 66,410 K in profit during its latest quarter, and -23,110 K in sales during its previous quarter.
